{
    "clinical_study": {
        "@rank": "159728", 
        "arm_group": {
            "arm_group_label": "Mesencephalic  Neuronal Precursor Cells", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic\n      Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease."
        }, 
        "brief_title": "Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Idiopathic Parkinson Disease", 
            "Primary Parkinsonism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Parkinsonian Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is phase I/II clinical trials which is accessible to those involved in the study\n      and conducted by only Bundang CHA hospital.\n\n      The progress of the clinical trails is reported to and evaluated by  Data monitoring\n      committee before the enrolment of next human subject."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female patients with idiopathic or primary Parkinson's disease\n\n          2. Hoehn and Yare (HY) stage III or IV\n\n          3. more than 33% improvement Part III UPDRS score after one injection of      levodopa\n             in the morning\n\n          4. Patients aged less than 70\n\n          5. Great decrease of dopamine uptake in putamen, particularly posterior part, in\n             Positron emission tomograph(PET) before surgery\n\n        Exclusion Criteria:\n\n          1. Atypical or secondary parkinsonism\n\n          2. Medical history of severe depression with Beck Depression Inventory(BDI) scores\n             greater than 30\n\n          3. Psychological disorders (illusion, delusion, schizophrenia)\n\n          4. Dementia with K-MMSE(Korean mini-mental state examination) scores less than 24\n\n          5. Epilepsy\n\n          6. Medial history of brain surgery\n\n          7. Medical history of other brain diseases\n\n          8. Hemorrhagic tendency\n\n          9. Severe internal diseases such as poor general condition, hypertension, chronic\n             respiratory disease, ischemic heart disease, cancer\n\n         10. Experience of participating in clinical trial within 30 days\n\n         11. Female patients who have the chances of getting pregnant during clinical trial and do\n             not use the approved birth controls\n\n         12. Pregnant or lactating women\n\n         13. Patients who are not considered to be eligible to participate in clinical trial"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860794", 
            "org_study_id": "PBC09-074"
        }, 
        "intervention": {
            "arm_group_label": "Mesencephalic  Neuronal Precursor Cells", 
            "description": "All the  patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.", 
            "intervention_name": "Mesencephalic Neuronal Precursor Cells", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dopamine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "contact": {
                "email": "sschung@cha.ac.kr", 
                "last_name": "Sang Sup Chung, M.D., Ph.D.", 
                "phone": "82-31-780-5261"
            }, 
            "contact_backup": {
                "email": "hanib@cha.ac.kr", 
                "last_name": "In Bo Han, M.D., Ph.D.", 
                "phone": "82-31-780-5688"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "463-712"
                }, 
                "name": "CHA Bundang Medical Center, CHA University"
            }, 
            "investigator": [
                {
                    "last_name": "Sang Sup Chung, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "In Bo Han, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joo Pyung Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yong Soo Choi, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hyun Sook Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Won Chan Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sang Heum Kim, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eun Hye Yoo, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Su Jin Jang, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease", 
        "overall_contact": {
            "email": "sschung@cha.ac.kr", 
            "last_name": "Sang Sup Chung, M.D., Ph.D.", 
            "phone": "82-31-780-5261"
        }, 
        "overall_contact_backup": {
            "email": "hanib@cha.ac.kr", 
            "last_name": "In Bo Han, M.D., Ph.D.", 
            "phone": "82-31-780-5688"
        }, 
        "overall_official": {
            "affiliation": "CHA University", 
            "last_name": "Sang Sup Chung, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "If not included in the following criteria, the cells are are considered to be safe and tolerable.\nCells with grade 3 or more in NCI grading system\nCells contaminated with infectious materials\nCells with risk of cancer formation", 
            "measure": "Presence or absence of cancer foramtion and infection", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860794"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bundang CHA Hospital", 
            "investigator_full_name": "Sang Sup Chung", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "UPDRS, most commonly used, is designed to assess the severity of parkinson's disease, making the quantitative measurement of the extent. Part III of UPDRS corresponds to motor evaluation and is the most reliable for detecting symptomatic progression.\nUPDRS improvement ratio(%) = ((the value of UPDRS before surgery - the value of UPDRS after surgery) / (the value of UPDRS before surgery)) X 100", 
                "measure": "Score of Unified Parkinson's Disease Rating Scale (UPDRS)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "In pet analysis, putamen activity is investigated via radioactivity before cell transplantation and 12,24,36,48,60 months after the treatment.", 
                "measure": "Detection of positron emission in Putamen using Positron emission tomograph(PET)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Overall  inspection was carried out before transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60 months after the treatment for determining whether the cells have therapeutic effects.", 
                "measure": "Dyskinesia scale scores(CAPSIT-PD)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Comprehensive clinical assessment for examining  the improvements in self reporting and timed testing before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment:Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test.", 
                "measure": "Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Comprehensive clinical assessment for examining the improvements in activity of daily living before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Score of activity of daily living (ADL) scale", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Comprehensive clinical assessment for examining the improvements in mental state before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Score of Korean mini-mental examination (K-MMSE)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Comprehensive clinical assessment for identifying the presence of motor fluctuation symptoms before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Motor fluctuation scale scores", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Measure of patient satisfaction before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Satisfaction score with patient questionnaire", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Measure of dopaminergic drug dose before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Dopaminergic drug dose", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Using video recording, assessment for symptoms such as tremor, postural instability, motor dysfunction and gait disturbance  before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Tremor, postural instability, motor dysfunction, gait disturbance", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Assessing the extent of recovery based on patient's diary before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.", 
                "measure": "Assessing the extent of recovery with patient's diary", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Bundang CHA Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bundang CHA Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}